• 1
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78-93.
  • 2
    Wiggins CL, Espey DK, Wingo PA, et al. Cancer among American Indians and Alaska Natives in the United States, 1999-2004. Cancer. 2008; 113( 5 suppl): 1142-1152.
  • 3
    Bliss A, Cobb N, Solomon T, et al. Lung cancer incidence among American Indians and Alaska Natives in the United States, 1999-2004. Cancer. 2008; 113( 5 suppl): 1168-1178.
  • 4
    Sugarman JR, Dennis LK, White E. Cancer survival among American Indians in western Washington State (United States). Cancer Causes Control. 1994; 5: 440-448.
  • 5
    Wang SJ, Fuller CD, Thomas CRJr. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol. 2007; 2: 180-190.
  • 6
    Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007; 25: 5570-5577.
  • 7
    Horner MR, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; Year [serial online]. Available at: Accessed March 22, 2010.
  • 8
    National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Website [serial online]. Available at: Accessed March 22, 2010.
  • 9
    FritzA, PercyC, JackA, et al. (eds). International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 10
    Zell JA, Ou SH, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol. 2005; 23: 8396-8405.
  • 11
    Franklin WA, Chanin T, Gonzalez A. Molecular and cellular pathology of lung cancer. In: PassHI, MitchellJB, JohnsonDH, TurrisiAT, MinnaJD, CarboneDP, eds. Lung Cancer: Principles and Practices. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 235-238.
  • 12
    Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers–a different disease. Nat Rev Cancer. 2007; 7: 778-790.
  • 13
    Eichner JE, Cravatt K, Beebe LA, et al. Tobacco use among American Indians in Oklahoma: an epidemiologic view. Public Health Rep. 2005; 120: 192-199.
  • 14
    Davis WW, Hartman AM, Gibson JT. Trends in Smoking Prevalence by Race based on the Tobacco Use Supplement to the Current Population Survey. Bethesda, MD: National Cancer Institute [monograph online]. Available at: Accessed March 22, 2010.
  • 15
    Dennis TD. Cancer stage at diagnosis, treatment, and survival among American Indians and non-American Indians in Montana. Cancer. 2000; 89: 181-186.
  • 16
    Daniels LJ, Balderson SS, Onaitis MW, et al. Thoracoscopic lobectomy: a safe and effective strategy for patients with stage I lung cancer. Ann Thorac Surg. 2002; 74: 860-864.
  • 17
    Kirby TJ, Mack MJ, Landreneau RJ, et al. Lobectomy–video-assisted thoracic surgery versus muscle-sparing thoracotomy. A randomized trial. J Thorac Cardiovasc Surg. 1995; 109: 997-1001; discussion 1001-1002.
  • 18
    Demmy TL, Curtis JJ. Minimally invasive lobectomy directed toward frail and high-risk patients: a case-control study. Ann Thorac Surg. 1999; 68: 194-200.
  • 19
    Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc. 2009; 6: 194-200.
  • 20
    Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350: 351-360.
  • 21
    Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol. 2007; 25: 1553-1561.
  • 22
    Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7: 719-727.
  • 23
    Lang K, Marciniak MD, Faries D, et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer. 2009; 63: 264-270.
  • 24
    Morgensztern D, Goodgame B, Baggstrom MQ, et al. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol. 2008; 3: 135-139.
  • 25
    Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010; 340: b5569.
  • 26
    Janjigian YY, McDonnell K, Kris MG, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2009; 116: 670-675.
  • 27
    Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009; 27: 5816-5822.
  • 28
    Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003; 349: 2117-2127.
  • 29
    Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med. 2001; 345: 181-188.